The State of the Art in Combination Locoregional and Systemic Treatment Strategies for Hepatocellular Carcinoma: Recent Advancements and Future Horizons

TL;DR

This paper reviews recent advancements in combining local and systemic treatments for liver cancer, highlighting improved patient outcomes and future research directions.

Contribution

The paper provides a comprehensive review of recent clinical trials and strategies combining locoregional and systemic therapies for hepatocellular carcinoma.

Findings

Combining local and systemic treatments may improve survival and make patients eligible for curative surgery.

Trials like KEYNOTE-937 and CheckMate 9DX show combination therapies can extend treatment responses.

Ongoing studies aim to determine optimal treatment sequencing and patient selection.

Abstract

Liver cancer, specifically hepatocellular carcinoma, is one of the most common cancers and a leading cause of cancer death worldwide. Many patients are diagnosed at stages when surgery or liver transplant is no longer possible, leaving them with limited treatment options. Local tumor treatments, such as those that destroy cancer cells with heat or cold or those that cut off tumor blood supply, provide important alternatives for these patients. Numerous clinical trials have evaluated whether combining these local treatments with medications that boost the immune system or stop tumor growth can improve patient outcomes. This review examines progress made over the past two decades in developing these combination treatment approaches. Early evidence suggests that combining local and systemic treatments is generally safe and may help patients live longer, slow cancer progression, and in some cases reduce disease severity enough to make patients eligible for potentially curative surgery or transplant. However, questions remain about which combinations work best, when treatments should be given, and which patients benefit most. Focused discussion of completed and ongoing studies is essential to synthesize emerging evidence, inform optimal treatment strategies, and guide care in this rapidly evolving field.

Hepatocellular carcinoma remains one of the most common and lethal cancers worldwide, and many patients are diagnosed at stages where curative therapy is not possible. Recent progress in systemic therapies and refinements in locoregional treatment have shifted how clinicians approach this disease. As evidence has accumulated from trials such as KEYNOTE-937, IMbrave050, and CheckMate 9DX, it has become clear that pairing immunotherapy with ablation or transarterial interventions can deepen and extend treatment responses compared with using either approach alone. This review summarizes the current landscape of these combination strategies, explains the biological and clinical principles that support their use, and highlights ongoing trials that aim to clarify optimal sequencing and patient selection. It also considers future directions for integrating locoregional and systemic therapies to expand curative opportunities and improve long-term outcomes for a broader range of patients.